

PUBLIC SUMMARY DOCUMENT

Product: Hollister Apogee Intermittent Catheter
Applicant: Hollister
Date of SPAP Meeting: Out-of-Session – 20 March 2020

1. Proposed Variation on the Stoma Appliance Scheme

The applicant, Hollister, advised of a global manufacturing change for the entire range of the existing listing of the Hollister Apogee Intermittent Catheter (SAS Code 80158W) in subgroup 8(c) of the Stoma Appliance Scheme (the Scheme) Schedule. The product, including eleven variants, is currently listed at a unit price of \$1.034, with a maximum monthly quantity of 120 units.

2. Variation details

The applicant advised of a global manufacturing change to the funnel for the existing listing of SAS Code 80158W. The applicant has advised the enhanced funnel is more flexible.

Product Code	Description
10616	Apogee Essentials Intermittent Catheter nelaton Male 6Fr40cm,
10806	Apogee Essentials Intermittent Catheter nelaton Female 8Fr 15cm,
10816	Apogee Essentials Intermittent Catheter nelaton Male 8Fr 40cm,
11006	Apogee Essentials Intermittent Catheter nelaton Female 10Fr 15cm,
11016	Apogee Essentials Intermittent Catheter nelaton Male 10Fr 40cm,
11206	Apogee Essentials Intermittent Catheter nelaton Female 12Fr 15cm,
11216	Apogee Essentials Intermittent Catheter nelaton Male 12Fr 40cm,
11406	Apogee Essentials Intermittent Catheter nelaton Female 14Fr 15cm,
11416	Apogee Essentials Intermittent Catheter nelaton Male 14Fr 40cm,
11616	Apogee Essentials Intermittent Catheter nelaton Male 16Fr 40cm,
11816	Apogee Essentials Intermittent Catheter nelaton Male 18Fr 40cm,

3. Background

This product was first listed on the SAS Schedule in May 2018.

4. Clinical Place for the Product

The proposed product provides an alternative for users requiring an intermittent catheter.

Financial Analysis

Not applicable

5. SPAP Recommendation

The SPAP noted the change to the funnel for the existing listing for the Hollister Apogee Intermittent Catheter (SAS Code 80158W) listed in subgroup 8(c), of the Scheme Schedule at the unit price of \$1.034, with a maximum monthly quantity of 120 units.

The SPAP also noted that Hollister is to advise Stoma Associations, ostomates, Stomal Therapy Nurses and ACSA of the product description change.

6. Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

7. Applicant's Comment

Hollister agrees with the Panel's recommendation.